Research programme: hypoxia inducible factor inhibitors - ELARAAlternative Names: EL102
Latest Information Update: 04 May 2011
At a glance
- Originator Elara Pharmaceuticals
- Class Small molecules
- Mechanism of Action Hypoxia-inducible factor 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 16 Nov 2010 Preclinical development is ongoing in Germany (PO)
- 06 Aug 2009 Preclinical trials in Cancer in Germany (PO)